VIVUS
CompanyUnited States
VIVUS develops 2 assets, the furthest in phase 2 (phentermine/topiramate in diabetes). Mostly small molecule acting on lipid and ceramide metabolism, SLC6A2 and GABRA1; based in the United States.
- Assets
- 2
- Furthest
- Phase 2
- Trials
- 9
- Signals
- 0
Pipeline
2Sympathomimetic amine anorectic and neurotherapeutic agent combination suppressing appetite.
Phase 2Small moleculeLipid and ceramide metabolismSLC6A2diabeteshepatic impairment (Phase 1)
Fixed-dose combination product containing metformin for obesity and metabolic regulation
Phase 1Small moleculeAMPK signallingInsulin/IGF-1 signallingobesity
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms6
- Trials10
- Similar companies6
Updated 7 Oct 2026 · 20 sources